The Elizabeth Selvin Lab examines the intersection of epidemiology, clinical policy and public ...health policy. One of our key goals is to use the findings of epidemiologic research to inform the screening, diagnosis and treatment of diabetes, cardiovascular disease and kidney disease. Much of our work looks at biomarkers and diagnostics related to diabetes and diabetes complications. Our findings — linking hemoglobin A1c (HbA1c) to diabetic complications and identifying the role of A1c in diabetes diagnosis — have influenced clinical practice guidelines. view more

The Foster Lab uses the tools of protein biochemistry and proteomics to tackle fundamental prob...lems in the fields of cardiac preconditioning and heart failure. Protein networks are perturbed in heart disease in a manner that correlates only weakly with changes in mRNA transcripts. Moreover, proteomic techniques afford the systematic assessment of post-translational modifications that regulate the activity of proteins responsible for every aspect of heart function from electrical excitation to contraction and metabolism. Understanding the status of protein networks in the diseased state is, therefore, key to discovering new therapies.

D. Brian Foster, Ph.D., is an assistant professor of medicine in the division of cardiology, and serves as Director of the Laboratory of Cardiovascular Biochemistry at the Johns Hopkins University School of Medicine.


view more

Research in the Gail Daumit Lab is devoted to improving overall health and decreasing premature... mortality for people with serious mental illnesses, such as schizophrenia and bipolar disorder. We have conducted observational studies to determine and convey the burden of physical health problems in this vulnerable population, and are currently leading a randomized trial funded by the National Heart, Lung, and Blood Institute to test a comprehensive cardiovascular risk reduction program in people with serious mental illness. view more

Work in the Hsin-Chieh Yeh Lab focuses on clinical trials and cohort studies of diabetes, obesi...ty and behavioral intervention, cancer and hypertension. Recent investigations have focused on novel risk factors and complications related to obesity and type 2 diabetes, particularly lung function, smoking and cancer. We recently co-led a randomized clinical trial of tailored dietary advice for consumption of dietary supplements to lower blood pressure and improve cardiovascular disease risk factors in hypertensive urban African Americans. view more

Our group is interested in a broad array of clinical and translational investigations spanning ...the evaluation of basic pathophysiology in patients undergoing cardiac procedures, development and evaluation of new therapeutic strategies, and improving patient selection and outcomes following interventional procedures. We are comprised of a core group of faculty and dedicated research nurses as well as fellows, residents, and students. Projects range from investigator-initiated single-center observational studies to industry-sponsored multicenter phase 3 randomized controlled trials. We have established a database of all patients who have undergone TAVR at Johns Hopkins, which is providing the basis for several retrospective analyses and will serve as the foundation for future studies of TAVR. We are also engaged in collaborative projects with other groups from the Department of Medicine and other Departments including Cardiac Surgery, Anesthesiology, Radiology, Psychiatry, and Biomedical Engineering. Members of our group are actively involved with the Johns Hopkins Center for Bioengineering Innovation and Design (CBID) in the development of novel minimally-invasive cardiovascular devices. view more

Research in the J. Hunter Young Lab focuses on the genetic epidemiology and physiology of cardi...ovascular disease and its risk factors, especially hypertension, diabetes and obesity. Current activities include an observational study of hypertension among African Americans; a genetic epidemiology study of worldwide cardiovascular disease susceptibility patterns; and several population-based observational studies of cardiovascular and renal disease. A recent focus group study found that changes in housing and city policies might lead to improved environmental health conditions for public housing residents. view more

Research in the Jochen Steppan Lab primarily focused on vascular stiffness related to aging. We... are currently researching LOXL2 (lysine-oxidase-like-2), which might be intimately involved in the development or progression of vascular stiffness. We aim to better understand LOXL2's role in the vasculature and hope that this work leads to the characterization of a novel therapeutic target. This is important in the treatment of cardiovascular diseases in the aging population. view more

Research in the Josef Coresh Lab focuses on cardiovascular epidemiology, kidney disease and gen...etic epidemiology. Our team uses innovative methods to quantify disease burden and consequences in the population; studies the causes and consequences of vascular disease in the heart, kidneys and brain; and works to develop a strong scientific basis for quantifying the burden, causes and consequences of kidney disease. Working in collaboration with leading laboratories and specialists, we also aim to quantify the interplay of genes and environment in health and disease. view more

Research in the Kathleen Gabrielson Laboratory focuses on the signal transduction of cardiovasc...ular toxicities in vitro, in cardiomyocyte culture and in vivo using rodent models. Specifically, the research focuses on understanding the mechanisms of various cancer therapies that induce cardiac toxicities.

Currently, we are testing prevention strategies for these toxicities by studying the cardiac effects of the anthracycline doxorubicin (adriamycin) and the immunotherapeutic agent, Herceptin, anti-erbB2. We are focusing on the signal transduction pathways in the heart that are modulated by anti-erbB2 treatment, which in turn, worsens doxorubicin toxicity. Thus, understanding the mechanisms behind the combined toxicity of doxorubicin and anti-erbB2 will pave the way for the design of strategies to reduce toxicity, identify patients at risk and potentially allow higher levels of this effective combination therapy to be used with an improved long-term survival in patients. view more